CENTANY Drug Patent Profile

When do Centany patents expire, and when can generic versions of Centany launch?

Centany is a drug marketed by Padagis Us and is included in one NDA.

The generic ingredient in CENTANY is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Centany

A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7^th, 2003.

Summary for CENTANY

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	2
Patent Applications:	7,767
What excipients (inactive ingredients) are in CENTANY?	CENTANY excipients list
DailyMed Link:	CENTANY at DailyMed

Recent Clinical Trials for CENTANY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Washington	Phase 2
St. Louis Children's Hospital	Phase 2
Cook Children's Medical Center	Phase 2

See all CENTANY clinical trials

US Patents and Regulatory Information for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002	BX	RX	No	No

Expired US Patents for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002	6,013,657

International Patents for CENTANY

See the table below for patents covering CENTANY around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2165723
Germany	69900561
Canada	2259764	COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA MUPIROCINE (PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN)
European Patent Office	0933081	Compositions pharmaceutiques contenant mupirocine (Pharmaceutical compositions containing mupirocin)
Israel	123143	PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN

Market Dynamics and Financial Trajectory for CENTANY (Mupirocin)

Last updated: February 20, 2026

What is CENTANY and its current market position?

CENTANY, with the active ingredient mupirocin, is a topical antibiotic indicated for the treatment of skin infections, including impetigo and secondary skin infections caused by gram-positive bacteria. It holds a niche position within the antibiotics segment, particularly in dermatology and hospital settings.

The drug first received FDA approval in 1991 and has maintained a steady presence owing to its efficacy against methicillin-resistant Staphylococcus aureus (MRSA).

What are the core market drivers and challenges?

Market Drivers:

• Rising prevalence of skin infections caused by resistant bacteria, especially MRSA, heightens demand for mupirocin.
• Increasing adoption of topical antibiotics in outpatient and hospital settings.
• Expandable use cases, including decolonization procedures for MRSA carriers in healthcare environments.

Market Challenges:

• Competition from oral antibiotics and alternative topical agents.
• Risk of resistance development limiting long-term effectiveness.
• Price pressures due to generic mupirocin availability and healthcare cost containment efforts.

How has the market for mupirocin evolved?

Market Size and Growth:

• The global dermatology antibiotics market was valued at approximately USD 1.2 billion in 2022.
• Mupirocin's share within this segment is estimated at USD 300 million.
• Compound annual growth rate (CAGR) projected at 4% between 2023-2028, driven by increased awareness and infection control protocols.

Geographic Trends:

• North America, particularly the U.S., commands over 60% of the market share owing to high prevalence of resistant infections and strong healthcare infrastructure.
• Europe accounts for about 20%, with growth driven by antimicrobial stewardship policies.
• Asia-Pacific exhibits rapid expansion, expected to grow at 6% CAGR, due to rising infection rates and evolving healthcare systems.

What are the financial trends for CENTANY and mupirocin sales?

Revenue Patterns:

• Estimated annual sales of mupirocin-based products, including CENTANY, hover near USD 250 million globally.
• U.S. sales account for USD 150 million, with steady growth recognized since product launch.
• Generic mupirocin accounts for a substantial portion, with branded CENTANY representing about 40-50% of sales.

Pricing and Competitive Dynamics:

• Branded CENTANY retails at approximately USD 80-100 per tube.
• Generics are priced around USD 20-40 per tube, causing significant market share competition.
• Patent expiry timelines influence future revenue prospects; original patents expired around 2010.

R&D and Pipeline Status:

• Few new formulations or delivery mechanisms in advanced development stages.
• Reliance on existing resistance profiles and infection control demands.

What are the implications for investors and industry players?

• Market maturity limits growth potential without innovation or expanding indications.
• Key opportunities exist in decolonization protocols, hospital-acquired infections, and resistant pathogen management.
• Competitive pressure from generics emphasizes the importance of brand differentiation and lifecycle management.
• Recovery prospects hinge on antimicrobial resistance trends and regulatory policies concerning antibiotic use.

Key market trends and future outlook

Trend	Implication
Resistance development	May reduce mupirocin effectiveness, prompting off-label use or alternative treatments
Rising healthcare spending	Supports continued demand, especially in hospital infection control
Antibiotic stewardship policies	Potentially constrains prescribing volumes but encourages targeted applications
Innovation in delivery systems	Potential to extend product lifecycle via improved formulations or combination therapies

Conclusion

Centany (mupirocin) maintains a stable market presence driven by the need to treat resistant bacterial skin infections. Market growth remains moderate owing to generic competition, but opportunities exist in infection control applications. The overall financial trajectory is expected to remain steady in the near term, with future prospects depending on resistance trends and product innovation.

Key Takeaways

• The mupirocin market, including CENTANY, is valued around USD 250 million globally, with North America dominating.
• Growth is steady, driven by infection control needs, but limited by generic competition and resistance concerns.
• Future revenue hinges on strategic positioning within hospital and outpatient care, plus potential pipeline developments.
• Pricing dynamics favor generics, challenging branded sales.
• Industry focus on antimicrobial stewardship impacts prescribing and product utilization.

FAQs

1. When did CENTANY receive FDA approval?
In 1991.

2. What is the main competitive threat to CENTANY?
Availability of generic mupirocin offers significantly lower prices, reducing branded product sales.

3. How does resistance affect mupirocin's market?
Development of mupirocin-resistant strains can diminish effectiveness, prompting shifts to alternative treatments.

4. What are the key geographic markets for mupirocin?
North America leads, followed by Europe and Asia-Pacific, which shows promising growth.

5. Are there new developments or formulations for mupirocin?
Few pipeline innovations exist; focus remains on optimizing existing formulations and expanding indication use.

---

References

1. MarketsandMarkets. (2022). Dermatology antibiotics market report.
2. U.S. Food and Drug Administration. (1991). Drug approval announcements.
3. IQVIA. (2023). Global prescription drug sales report.
4. World Health Organization. (2021). Antimicrobial resistance global report.
5. Grand View Research. (2023). Topical antibiotics market analysis.